References
- Bodur H, Ataman S, Rezvani A Quality of life and related variables in patients with ankylosing spondylitis. Qual Life Res. 2011;20:543–549. http://link.springer.com/article/10.1007/s11136-010-9771-9
- Petříková A, Doležal T, Klimeš J, et al. The economic burden of the ankylosing spondylitis in the Czech Republic: comparison between 2005 and 2008. Rheumatol Int. 2013;33:1813–1819. http://link.springer.com/article/10.1007/s00296-012-2542-x
- Kruntorádová K, Klimeš J, Šedová L, et al. Work productivity and costs related to patients with ankylosing spondylitis, rheumatoid arthritis, and psoriasis. Value Health Reg Issues. 2014;4:100–106. Available from: http://www.sciencedirect.com/science/article/pii/S2212109914000624
- Péntek M, Poór G, Wiland P, et al. Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries. Eur J Health Econ. 2014;15(suppl. 1):35–43. http://link.springer.com/article/10.1007/s10198-014-0592-6
- Kruntorádová K, Klimes J, Dolezal T, et al. PMS53 work productivity and productivity costs of patients with ankylosing spondylitis in the Czech Republic. Poster ISPOR European Congress 2011 (PMS53). Value Health. 2011;14:A312. http://www.valueinhealthjournal.com/article/S1098-3015(11)02001-8/pdf
- Kruntorádová K, Klimes J, Dolezal T, et al. PMS51 work productivity and productivity costs of patients with rheumatoid arthritis, ankylosing spondylitis and psoriasis in the Czech Republic. Poster ISPOR European congress 2012 (PMS51). Value Health. 2012;15:A448. http://www.valueinhealthjournal.com/article/S1098-3015(12)03119-1/pdf
- Mlcoch T, Jircikova J, Mandelikova M, et al. The impact of anti-Tnf (etanercept) therapy on work productivity in patients with rheumatoid arthritis, psoriatic arthritis and psoriasis in the Czech Republic. Value Health. 2015;18:A649. http://www.ispor.org/research_pdfs/51/pdffiles/PMS89.pdf
- Dean LE, Jones GT, MacDonald AG, et al. Global prevalence of ankylosing spondylitis. Rheumatology. 2014;53:650–657. http://rheumatology.oxfordjournals.org/content/53/4/650.long
- Brazier JE, Yang Y, Tsuchiya A, et al. A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ. 2010;11:215–225. http://link.springer.com/article/10.1007%2Fs10198-009-0168-z
- Kearns B, Ara R, Wailoo A, et al. Good practice guidelines for the use of statistical regression models in economic evaluations. Pharmacoeconomics. 2013;31:643–652. http://link.springer.com/article/10.1007/s40273-013-0069-y
- NICE technology appraisal guidance [TA233]: golimumab for the treatment of ankylosing spondylitis [Internet]. Aug 2011. [cited 2016 May 17]. Available from: https://www.nice.org.uk/guidance/ta233/ (guidance has been updated to https://www.nice.org.uk/guidance/ta383; but the original guidance is available upon request).
- Kontodimopoulos N, Bozios P, Yfantopoulos J, et al. Longitudinal predictive ability of mapping models: examining post-intervention EQ-5D utilities derived from baseline MHAQ data in rheumatoid arthritis patients. Eur J Health Econ. 2013;14:307–314. http://link.springer.com/article/10.1007/s10198-012-0376-9
- Dakin H Review of studies mapping from quality of life or clinical measures to EQ-5D: an online database [cited 2016 May 17]. Health Qual Life Outcomes. 2013;11. Available from: http://hqlo.biomedcentral.com/articles/10.1186/1477-7525-11-151
- Gaujoux-Viala C, Fautrel B Cost effectiveness of therapeutic interventions in ankylosing spondylitis: a critical and systematic review. Pharmacoeconomics. 2012;30:1145–1156. http://link.springer.com/article/10.2165%2F11596490-000000000-00000
- Van Der Linden SVD, Valkenburg HA, Cats A Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis. 1984; & Rheumatism 27:361–368. http://onlinelibrary.wiley.com/doi/10.1002/art.1780270401/abstract;jsessionid=BAA1F3E274C0D4F6DA9B877B3E8E6A3A.f04t02
- Braun J, Van Der Heijde D, Dougados M, et al. Staging of patients with ankylosing spondylitis: a preliminary proposal. Ann Rheum Dis. 2002;61(Supplement 3):iii19–iii23. http://ard.bmj.com/content/61/suppl_3/iii19.long
- Ankylosing Spondylitis Disease Activity Score (ASDAS), Asessment of Spondyloarthritis. International Socienty [Internet]. [cited 2016 May 17]. Available from: http://www.asas-group.org/clinical-instruments/asdas_calculator/asdas.html
- Bath Ankylosing Spondylitis Functional Index (BASFI) [Internet]. [cited 2016 May 17]. Available from: http://basdai.com/BASFI.php
- EuroQol Office [Internet]. EQ-5D. [cited 2016 May 17]. Available from: http://www.euroqol.org/
- Szende A, Oppe M, Devlin N EQ-5D value sets: inventory, comparative review and user guide [Internet]. [cited 2016 May 17]. EuroQol Group Monographs. Springer; 2007. Available from: http://www.springer.com/gp/book/9781402055102
- Reilly Associates. Work productivity and activity impairment questionnaire [Internet]. [cited 2016 May 17]. Available from: http://www.reillyassociates.net/WPAI_General.html
- Wailoo A, Hernández M, Philips C, et al. Modeling health state utility values in ankylosing spondylitis: comparisons of direct and indirect methods. Value Health. 2015;18:425–431. http://www.sciencedirect.com/science/article/pii/S1098301515018537
- Angrist DJ, Pischke J Mostly harmless econometrics: an empiricist’s companion [Internet]. Princeton University Press; 2009 [cited 2016 May 17].. Available from: http://press.princeton.edu/titles/8769.html
- Bell A, Jones K Explaining fixed effects: random effects modeling of time-series cross-sectional and panel data. Political Sci Res Methods. 2015;3:133–153. http://journals.cambridge.org/action/displayAbstract?fromPage=online&aid=9452105&fileId=S2049847014000077
- Wailoo AJ, Hernandez-Alava M, Martinez AE Modelling the relationship between the WOMAC osteoarthritis index and EQ-5D. Health Qual Life Outcomes. 2014;12:37. http://hqlo.biomedcentral.com/articles/10.1186/1477-7525-12-37
- Hernández Alava M, Wailoo AJ, Ara R Tails from the peak district: adjusted limited dependent variable mixture models of EQ-5D questionnaire health state utility values. Value Health. 2012;15:550–561. http://www.sciencedirect.com/science/article/pii/S1098301512000150
- Basu A, Manca A Regression estimators for generic health-related quality of life and quality-adjusted life years. Med Decis Making. 2012;32:56–69.http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4575808/
- Mlčoch T, Klimeš J, Fila L, et al. Cost-of-illness analysis and regression modeling in cystic fibrosis: a retrospective prevalence-based study. Eur J Health Econ. Original Paper. 2016;1–10. http://link.springer.com/article/10.1007/s10198-015-0759-9
- Klimeš J, Vocelka M, Šedová L, et al. Medical and productivity costs of rheumatoid arthritis in the Czech Republic: cost-of-illness study based on disease severity. Value Health Reg Issues. 2014;4:75–81. http://www.sciencedirect.com/science/article/pii/S2212109914000582
- Barbieri M, Drummond M, Rutten F, et al. What do International pharmacoeconomic guidelines say about economic data transferability?. Value Health. 2010;13:1028–1037. http://www.valueinhealthjournal.com/article/S1098-3015(11)71836-8/pdf
- Doward LC, Spoorenberg A, Cook SA, et al. Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis. 2003;62:20–26. http://ard.bmj.com/content/62/1/20.long
- Gray AM, Clarke PM, Wolstenholme JL, et al. Applied methods of cost-effectiveness analysis in health care. Oxford: Oxford University Press; 2011.